RxDoctor Payments Data

Hannah Bushnell, DO

Psychiatry · Elmira, NYNPI 1174937288

Payments from drug & device makers

$19,153in general payments, 2019–2025

Across 250 payments — averaging $76.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$16K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$486
  • Neurocrine Biosciences, Inc.$312
  • Teva Pharmaceuticals USA, Inc.$274
  • Sunovion Pharmaceuticals Inc.$225
  • plus $852 from 10 others

What the payments were for

  • Speaking & faculty fees$11,69061%
  • Travel & lodging$2,58814%
  • Food & beverage$4,80525%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,153 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$38,218
Medicare patients
45
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl113$369,905
VraylarCariprazine Hcl14$19,396
TrintellixVortioxetine Hydrobromide31$17,896
Lurasidone Hcl16$14,973
AuvelityDextromethorphan Hbr/Bupropion11$11,761
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$1,970
Duloxetine Hcl26$1,572
Divalproex Sodium ErDivalproex Sodium23$1,243
Quetiapine Fumarate30$726
Bupropion XlBupropion Hcl27$713
Clonazepam39$662
Gabapentin17$413
Fluoxetine Hcl20$406
Bupropion Hcl SrBupropion Hcl14$391
Ramelteon11$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$15,779$369,905113 claims
AbbVieVraylar$1,225$19,39614 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$57$17,89631 claims
Axsome Therapeutics, Inc.Auvelity$96$11,76111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Elmira

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →